A number of other research firms have also recently issued reports on CTMX. BidaskClub cut CytomX Therapeutics from a buy rating to a hold rating in a research report on Thursday, December 7th. Zacks Investment Research cut CytomX Therapeutics from a hold rating to a sell rating in a research report on Monday, February 19th. ValuEngine cut CytomX Therapeutics from a hold rating to a sell rating in a research report on Friday, December 1st. Finally, Citigroup began coverage on CytomX Therapeutics in a research report on Friday, January 5th. They issued a buy rating and a $40.00 price target on the stock. Three research analysts have rated the stock with a sell rating, two have issued a hold rating, eight have issued a buy rating and one has given a strong buy rating to the stock. The stock currently has a consensus rating of Buy and an average target price of $35.67.
CytomX Therapeutics (CTMX) traded up $1.62 on Thursday, hitting $34.10. The stock had a trading volume of 308,262 shares, compared to its average volume of 363,871. The company has a market capitalization of $1,316.64, a PE ratio of -28.90 and a beta of 0.76. CytomX Therapeutics has a 1-year low of $12.51 and a 1-year high of $35.00.
A number of large investors have recently made changes to their positions in the business. Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp bought a new stake in CytomX Therapeutics in the fourth quarter valued at $422,000. Sterling Capital Management LLC acquired a new position in CytomX Therapeutics in the fourth quarter worth $798,000. MetLife Investment Advisors LLC acquired a new position in CytomX Therapeutics in the fourth quarter worth $245,000. Iguana Healthcare Management LLC boosted its stake in CytomX Therapeutics by 7.1% in the fourth quarter. Iguana Healthcare Management LLC now owns 75,000 shares of the biotechnology company’s stock worth $1,583,000 after purchasing an additional 5,000 shares in the last quarter. Finally, Redmile Group LLC boosted its stake in CytomX Therapeutics by 9.5% in the fourth quarter. Redmile Group LLC now owns 418,680 shares of the biotechnology company’s stock worth $8,838,000 after purchasing an additional 36,409 shares in the last quarter. Hedge funds and other institutional investors own 78.50% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This piece was reported by Ticker Report and is the sole property of of Ticker Report. If you are accessing this piece on another publication, it was copied illegally and republished in violation of U.S. and international copyright & trademark law. The legal version of this piece can be viewed at https://www.tickerreport.com/banking-finance/3255775/cytomx-therapeutics-ctmx-given-a-40-00-price-target-by-cantor-fitzgerald-analysts-2.html.
About CytomX Therapeutics
CytomX Therapeutics, Inc is a clinical-stage, oncology-focused biopharmaceutical company. The Company uses its Probody technology platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against difficult-to-drug targets. Its pipeline is focused on the development of therapies in a set of modalities: Probody cancer immunotherapies, Probody drug conjugates, T-cell engaging Probody bispecifics and ProCAR-NK cell therapies.
Receive News & Ratings for CytomX Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.